Insmed (INSM) Operating Income (2010 - 2026)
Insmed (INSM) posted Operating Income of -$1.5 million for Q2 2026, up 98.99% on a QoQ basis from -$153.3 million in Q1 2026, and up 99.51% year-over-year from -$775919.5 in Q2 2025.
Analysis
Insmed (INSM) Operating Income (2010 - 2026) Analysis & Trends
Insmed has reported Operating Income for 17 years, with the latest figure at -$1.5 million in Q2 2026.
- On a quarterly basis, Operating Income rose 99.51% year-over-year to -$1.5 million in Q2 2026; TTM through Jun 2026 was -$840.6 million, a 16.34% increase from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 41.96% from the prior year.
- Operating Income was -$1.5 million for Q2 2026 at Insmed, up from -$153.3 million in the prior quarter.
- The five-year high for Operating Income was -$1.5 million in Q2 2026, with the low at -$366.0 million in Q3 2025.
- Average Operating Income over 5 years is -$191.5 million, with a median of -$165.8 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: Operating Income sank 166.69% in 2023, then surged 99.51% in 2026.
- Over 5 years, Operating Income stood at -$151.5 million in 2022, then dropped by 17.69% to -$178.3 million in 2023, then dropped by 29.25% to -$230.4 million in 2024, then tumbled by 38.77% to -$319.7 million in 2025, then soared by 99.52% to -$1.5 million in 2026.
- The last three Operating Income figures came in at -$1.5 million (Q2 2026), -$153.3 million (Q1 2026), and -$319.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.55 Mn |
| Mar 31, 2026 | -153.32 Mn |
| Dec 31, 2025 | -319.75 Mn |
| Sep 30, 2025 | -366.01 Mn |
| Jun 30, 2025 | -312.88 Mn |
| Mar 31, 2025 | -248.14 Mn |
| Dec 31, 2024 | -230.41 Mn |
| Sep 30, 2024 | -213.43 Mn |
| Jun 30, 2024 | -288.90 Mn |
| Mar 31, 2024 | -145.51 Mn |
| Dec 31, 2023 | -178.27 Mn |
| Sep 30, 2023 | -147.67 Mn |
| Jun 30, 2023 | -235.53 Mn |
| Mar 31, 2023 | -148.16 Mn |
| Dec 31, 2022 | -151.48 Mn |
| Sep 30, 2022 | -127.70 Mn |
| Jun 30, 2022 | -88.32 Mn |
| Mar 31, 2022 | -89.83 Mn |
| Dec 31, 2021 | -99.08 Mn |
| Sep 30, 2021 | -103.62 Mn |